Ankylosing Spondylitis - Global Market Outlook (2019 -2027)

   |      |      |  

Ankylosing Spondylitis - Global Market Outlook (2019 -2027)

Global Ankylosing Spondylitis Market is accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027 growing at a CAGR of 10.3% during the forecast period. Rising prevalence of Ankylosing Spondylitis, growing awareness about diagnostics and treatments for the disease. Additionally, government initiatives and getting better healthcare infrastructure are the major factors propelling the market growth. However, the huge cost of treatment and lack of skilled surgeons and physiotherapists are hampering the market growth.

Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a kind of arthritis, in which spine bones grow or fuse together, causing the spine to turn into rigid. Symptoms of ankylosing spondylitis comprise pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.

Based on the drugs, the humira segment is going to have a lucrative growth during the forecast period due to it’s a prescription medicine used to reduce the signs and symptoms of ankylosing spondylitis in adults. Humira can help to reduce the back pain, stiffness of AS, low cost and high efficiency.

By geography, North America is going to have a lucrative growth during the forecast period due to the more prevalence of the disease and amplified adoption of ankylosing spondylitis treatment options in the region. In addition, technological developments are driving ankylosing spondylitis treatment in this region.

Some of the key players profiled in the Ankylosing Spondylitis Market include Abbvie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc, Merck & Co, Novartis AG, Pfizer, Regeneron Pharmaceuticals, Sanofi, Shanghai Pharmaceuticals and UCB, Inc.

Molecule Types Covered:
• Biologics
• Biosimilars
• Small Molecules

Route of Administrations Covered:
• Oral
• Parenteral

Dosage Forms Covered:
• Liquid
• Solid

Drugs Covered:
• Cimzia
• Cosentyx
• Enbrel
• Humira
• Remicade
• Simponi

Drug Types Covered:
• Anti-Inflammatory Drugs 
• COX Inhibitors 
• Disease-Modifying Anitrheumatic Drugs (DMARDs) 
• Immunosuppressive Drugs 
• JAK Inhibitors 
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 
• Steroids 
• TNF Inhibitors 
• IL-17 Inhibitors 

Treatment Types Covered:
• Medication
• Surgery
• Therapy

Applications Covered:
• Adults
• Juveniles

End Users Covered:
• Hospital
• Care Home
• Clinic

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2018, 2019 2020, 2024, and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances 

1 Executive Summary        
          
2 Preface         
 2.1 Abstract        
 2.2 Stake Holders       
 2.3 Research Scope       
 2.4 Research Methodology      
  2.4.1 Data Mining      
  2.4.2 Data Analysis      
  2.4.3 Data Validation      
  2.4.4 Research Approach      
 2.5 Research Sources       
  2.5.1 Primary Research Sources     
  2.5.2 Secondary Research Sources     
  2.5.3 Assumptions      
          
3 Market Trend Analysis       
 3.1 Introduction       
 3.2 Drivers        
 3.3 Restraints       
 3.4 Opportunities       
 3.5 Threats        
 3.6 Application Analysis      
 3.7 End User Analysis       
 3.8 Emerging Markets       
 3.9 Impact of Covid-19       
          
4 Porters Five Force Analysis       
 4.1 Bargaining power of suppliers      
 4.2 Bargaining power of buyers      
 4.3 Threat of substitutes      
 4.4 Threat of new entrants      
 4.5 Competitive rivalry       
          
5 Global Ankylosing Spondylitis Market, By Molecule Type    
 5.1 Introduction       
 5.2 Biologics        
 5.3 Biosimilars       
 5.4 Small Molecules       
          
6 Global Ankylosing Spondylitis Market, By Route of Administration   
 6.1 Introduction       
 6.2 Oral        
 6.3 Parenteral       
          
7 Global Ankylosing Spondylitis Market, By Dosage Form    
 7.1 Introduction       
 7.2 Liquid        
 7.3 Solid        
          
8 Global Ankylosing Spondylitis Market, By Drug     
 8.1 Introduction       
 8.2 Cimzia        
 8.3 Cosentyx        
 8.4 Enbrel        
 8.5 Humira        
 8.6 Remicade       
 8.7 Simponi        
          
9 Global Ankylosing Spondylitis Market, By Drug Type    
 9.1 Introduction       
 9.2 Anti-Inflammatory Drugs      
 9.3 COX Inhibitors       
 9.4 Disease-Modifying Anitrheumatic Drugs (DMARDs)    
 9.5 Immunosuppressive Drugs      
 9.6 JAK Inhibitors       
 9.7 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)    
 9.8 Steroids        
 9.9 TNF Inhibitors       
 9.10 IL-17 Inhibitors       
          
10 Global Ankylosing Spondylitis Market, By Treatment Type    
 10.1 Introduction       
 10.2 Medication       
 10.3 Surgery        
 10.4 Therapy        
          
11 Global Ankylosing Spondylitis Market, By Application    
 11.1 Introduction       
 11.2 Adults        
 11.3 Juveniles        
          
12 Global Ankylosing Spondylitis Market, By End User     
 12.1 Introduction       
 12.2 Hospital        
 12.3 Care Home       
 12.4 Clinic        
          
13 Global Ankylosing Spondylitis Market, By Geography    
 13.1 Introduction       
 13.2 North America       
  13.2.1 US       
  13.2.2 Canada       
  13.2.3 Mexico       
 13.3 Europe        
  13.3.1 Germany       
  13.3.2 UK       
  13.3.3 Italy       
  13.3.4 France       
  13.3.5 Spain       
  13.3.6 Rest of Europe      
 13.4 Asia Pacific       
  13.4.1 Japan       
  13.4.2 China       
  13.4.3 India       
  13.4.4 Australia       
  13.4.5 New Zealand      
  13.4.6 South Korea      
  13.4.7 Rest of Asia Pacific      
 13.5 South America       
  13.5.1 Argentina      
  13.5.2 Brazil       
  13.5.3 Chile       
  13.5.4 Rest of South America     
 13.6 Middle East & Africa      
  13.6.1 Saudi Arabia      
  13.6.2 UAE       
  13.6.3 Qatar       
  13.6.4 South Africa      
  13.6.5 Rest of Middle East & Africa     
          
14 Key Developments        
 14.1 Agreements, Partnerships, Collaborations and Joint Ventures   
 14.2 Acquisitions & Mergers      
 14.3 New Product Launch      
 14.4 Expansions       
 14.5 Other Key Strategies      
          
15 Company Profiling        
 15.1 Abbvie        
 15.2 Amgen        
 15.3 Boehringer Ingelheim      
 15.4 Bristol-Myers Squibb      
 15.5 Celgene        
 15.6 Celltrion        
 15.7 Eisai        
 15.8 Eli Lilly and Company      
 15.9 F. Hoffmann-La Roche      
 15.10 Janssen Pharmaceuticals      
 15.11 Johnson & Johnson Services, Inc     
 15.12 Merck & Co       
 15.13 Novartis AG       
 15.14 Pfizer        
 15.15 Regeneron Pharmaceuticals      
 15.16 Sanofi        
 15.17 Shanghai Pharmaceuticals      
 15.18 UCB, Inc        

 

Ankylosing Spondylitis - Global Market Outlook (2019 -2027)

List of Tables         
Table 1 Global Ankylosing Spondylitis Market Outlook, By Region (2018-2027) ($MN)  
Table 2 Global Ankylosing Spondylitis Market Outlook, By Molecule Type (2018-2027) ($MN) 
Table 3 Global Ankylosing Spondylitis Market Outlook, By Biologics (2018-2027) ($MN)  
Table 4 Global Ankylosing Spondylitis Market Outlook, By Biosimilars (2018-2027) ($MN)  
Table 5 Global Ankylosing Spondylitis Market Outlook, By Small Molecules (2018-2027) ($MN) 
Table 6 Global Ankylosing Spondylitis Market Outlook, By Route of Administration (2018-2027) ($MN)
Table 7 Global Ankylosing Spondylitis Market Outlook, By Oral (2018-2027) ($MN)  
Table 8 Global Ankylosing Spondylitis Market Outlook, By Parenteral (2018-2027) ($MN)  
Table 9 Global Ankylosing Spondylitis Market Outlook, By Dosage Form (2018-2027) ($MN)  
Table 10 Global Ankylosing Spondylitis Market Outlook, By Liquid (2018-2027) ($MN)  
Table 11 Global Ankylosing Spondylitis Market Outlook, By Solid (2018-2027) ($MN)  
Table 12 Global Ankylosing Spondylitis Market Outlook, By Drug (2018-2027) ($MN)  
Table 13 Global Ankylosing Spondylitis Market Outlook, By Cimzia (2018-2027) ($MN)  
Table 14 Global Ankylosing Spondylitis Market Outlook, By Cosentyx (2018-2027) ($MN)  
Table 15 Global Ankylosing Spondylitis Market Outlook, By Enbrel (2018-2027) ($MN)  
Table 16 Global Ankylosing Spondylitis Market Outlook, By Humira (2018-2027) ($MN)  
Table 17 Global Ankylosing Spondylitis Market Outlook, By Remicade (2018-2027) ($MN)  
Table 18 Global Ankylosing Spondylitis Market Outlook, By Simponi (2018-2027) ($MN)  
Table 19 Global Ankylosing Spondylitis Market Outlook, By Drug Type (2018-2027) ($MN)  
Table 20 Global Ankylosing Spondylitis Market Outlook, By Anti-Inflammatory Drugs (2018-2027) ($MN)
Table 21 Global Ankylosing Spondylitis Market Outlook, By COX Inhibitors (2018-2027) ($MN) 
Table 22 Global Ankylosing Spondylitis Market Outlook, By Disease-Modifying Anitrheumatic Drugs (DMARDs) (2018-2027) ($MN)
Table 23 Global Ankylosing Spondylitis Market Outlook, By Immunosuppressive Drugs (2018-2027) ($MN)
Table 24 Global Ankylosing Spondylitis Market Outlook, By JAK Inhibitors (2018-2027) ($MN) 
Table 25 Global Ankylosing Spondylitis Market Outlook, By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (2018-2027) ($MN)
Table 26 Global Ankylosing Spondylitis Market Outlook, By Steroids (2018-2027) ($MN)  
Table 27 Global Ankylosing Spondylitis Market Outlook, By TNF Inhibitors (2018-2027) ($MN) 
Table 28 Global Ankylosing Spondylitis Market Outlook, By IL-17 Inhibitors (2018-2027) ($MN) 
Table 29 Global Ankylosing Spondylitis Market Outlook, By Treatment Type (2018-2027) ($MN) 
Table 30 Global Ankylosing Spondylitis Market Outlook, By Medication (2018-2027) ($MN)  
Table 31 Global Ankylosing Spondylitis Market Outlook, By Surgery (2018-2027) ($MN)  
Table 32 Global Ankylosing Spondylitis Market Outlook, By Therapy (2018-2027) ($MN)  
Table 33 Global Ankylosing Spondylitis Market Outlook, By Application (2018-2027) ($MN)  
Table 34 Global Ankylosing Spondylitis Market Outlook, By Adults (2018-2027) ($MN)  
Table 35 Global Ankylosing Spondylitis Market Outlook, By Juveniles (2018-2027) ($MN)  
Table 36 Global Ankylosing Spondylitis Market Outlook, By End User (2018-2027) ($MN)  
Table 37 Global Ankylosing Spondylitis Market Outlook, By Hospital (2018-2027) ($MN)  
Table 38 Global Ankylosing Spondylitis Market Outlook, By Care Home (2018-2027) ($MN)  
Table 39 Global Ankylosing Spondylitis Market Outlook, By Clinic (2018-2027) ($MN)  

 

.